HealthLinx LimitedABN 88 098 640 352576 Swan Street Richmond VIC...

HealthLinx Limited
ABN 88 098 640 352
576 Swan Street Richmond VIC 3121
Telephone: +61 3 9208 4200 I Facsimile: +61 3 9208 4201
www.healthlinx.com.au
HEALTHLINX CEO TO RESIGN AS OF 30THJUNE 2012
16 November 2011, Melbourne: Mr Nick Gatsios will resign as CEO of HealthLinx Limited
(ASX: HTX). Mr Gatsios was a founding director of the private company when it was
established in 2002 and has been CEO of the company since it listed on the ASX in 2006.
In a decision reached by both parties, Mr Gatsios will extend his contracted notice period by
two months to remain with the company as managing director until 30th June 2012. This
extended period will allow Mr Gatsios to complete current projects of strategic importance
to the company.
Dr Greg Rice (Chairman, HealthLinx Limited) and the Board acknowledge the extraordinary
contribution that Nick has made to develop and position the company on the global
markets. “The board and I thank Nick for his professionalism and commitment to the
company over the past nine years. As CEO, Nick managed the clinical trials and data
generation that underpin the company’s OvPlex™ ovarian cancer diagnostic” said Dr Rice.
“Nick has achieved many significant milestones with HealthLinx that really are extraordinary
given the size and resources that have been available to the company. With the successful
completion of the clinical trials, the company is entering a new phase with a major focus on
expanding its global marketing, distribution and sales. This is a very positive step for both
the company and Mr Gatsios and a hallmark of the company’s maturation in the
biotechnology sector. A new CEO will drive the implementation of this strategy over the
next 2-3 years”. Prof Rice added.
The market will be kept informed as further developments occur.
Enquiries
Greg Rice (HealthLinx Limited) +61 3 9208 4200
Rudi Michelson (Monsoon Communications) +61 3 9620 3333
About HealthLinx Limited (ASX:HTX)
HealthLinx Limited develops multiple biomarker tests to improve the detection and diagnosis of
diseases and for monitoring response to treatment.
The first commercial targets for develop have been diseases where there is a clear clinical need for
better diagnosis and/or prognosis, and include:
• Ovarian cancer diagnostic (OvPlex™) targeting US$270m pa market
• Prostate cancer targeting US$350m pa market
A biomarker is a specific biochemical in the body that changes with disease onset, progression or in